Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company specializing in neurology, will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. Ian Mortimer, President and CEO, will present on June 8 at 2:30 pm Eastern Time. A live webcast will be available on the company’s website, with archived recordings to follow. Xenon focuses on developing therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its financial results for Q1 2022, highlighting key developments in its clinical programs. The company is progressing towards an end-of-Phase 2 meeting with the FDA regarding XEN1101 for epilepsy, with Phase 3 initiation expected in H2 2022. Xenon has also initiated a Phase 2 trial for XEN1101 in major depressive disorder (MDD). Financially, the company recorded revenues of $8.8 million, up from $4.4 million YoY, but incurred a net loss of $19.7 million due to increased operational costs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2022 financial results on May 10, 2022, after U.S. market close. The company, focused on developing therapeutics for neurological disorders, particularly epilepsy, will host a conference call at 4:30 PM ET to discuss the results. Participants can join using the provided dial-in numbers, with international access available. The event will also be streamed live on the company's investor website. Further information about their ongoing pipeline and developments can be found online.
Xenon Pharmaceuticals (NASDAQ:XENE) has announced the initiation of the Phase 2 'X-NOVA' clinical trial to assess the efficacy and safety of XEN1101 in treating Major Depressive Disorder (MDD). The study will involve approximately 150 subjects and include placebo controls. The trial aims to evaluate the impact of XEN1101 on depressive and anhedonia symptoms over six weeks. Promising pre-clinical data and previous studies support the potential of XEN1101 as a novel treatment approach for MDD. Topline results are expected in 2023.
Xenon Pharmaceuticals, focused on neurology, announced its participation in key investor conferences. The Jefferies Biotech on the Bay Summit is scheduled for April 26-27, 2022, in Miami, FL, featuring one-on-one meetings. The Bloom Burton & Co. Healthcare Investor Conference will take place on May 2-3, 2022, in Toronto, with a presentation on May 3 at 11:30 am ET. Lastly, the RBC Capital Markets Global Healthcare Conference will occur on May 17-18, 2022, in New York, highlighted by a fireside chat on May 18 at 11:00 am ET. For further details, visit Xenon's investor page.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced participation in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference on April 11, 2022. The fireside chat will occur from 10:15-10:55 am Eastern Time, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO. Recordings of the presentation will be available post-event on their website. The company is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced participation in the Stifel 2022 CNS Days virtual conference on March 29, 2022. Management will engage in one-on-one investor meetings and a fireside chat from 11:00-11:25 am Eastern Time. Presenters include Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer.
The company focuses on developing innovative therapeutics for neurological disorders and has a pipeline aimed at addressing high unmet medical needs, particularly in epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its 2021 financial results, highlighting significant advancements in clinical trials, particularly for XEN1101, a treatment for epilepsy and major depressive disorder. The Phase 2b X-TOLE trial showed strong efficacy, prompting plans for a Phase 3 development in 2022. Financially, total revenue dropped to $18.4 million with a net loss of $78.9 million, attributed to increased R&D and administrative expenses. Xenon maintains a robust cash position of $551.8 million, sufficient to fund operations into at least 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will release its financial results for the year ended December 31, 2021, on March 1, 2022. This announcement follows the closing of U.S. financial markets. A conference call and live audio webcast will take place on the same day at 4:30 PM Eastern Time to discuss these results and provide a corporate update. The company focuses on developing therapies for neurological disorders, particularly epilepsy. Investors can access more details on their website for further updates and replay options.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company will conduct one-on-one investor meetings and a virtual fireside chat.
The chat is scheduled for 5:00-5:30 pm ET and will be presented by Ian Mortimer, the President and CEO. Attendees can access details and webcasts on the company’s website after the event.
Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.